1. A pharmaceutical composition for oral administration comprising a) montelukast or a salt thereof in an amount of about 10.4 mg b) levocetirizine or a salt thereof in an amount of 5.0 mg, lactose monohydrate, microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium and gidroksipropiltsellyulozu.2. A pharmaceutical composition according to claim 1, wherein the montelukast is present in form of Montelukast natriya.3. A pharmaceutical composition according to claim 1, characterized in that levocetirizine present as levocetirizine digidrohlorida.4. A pharmaceutical composition according to any one of claims 1-3, characterized in that said composition is in the form of fixed combinations doz.5. A pharmaceutical composition according to claim 4, characterized in that said composition is in the form tabletki.6. A pharmaceutical composition according to claim 5, characterized in that said tablet is coated with film obolochkoy.7. A pharmaceutical composition according to claim 1, characterized in that the microcrystalline cellulose and anhydrous dibasic calcium phosphate are present in a weight ratio of 1: 1.8. A process for preparing a pharmaceutical composition of montelukast or a salt thereof and levocetirizine or a salt thereof, comprising the steps of: a) blending montelukast sodium, lactose monohydrate, microcrystalline cellulose, anhydrous dibasic calcium phosphate and croscarmellose sodium b) dissolving the hydroxypropyl cellulose in a solvent to form a binder solution c) granulating the mixture of step a) with a binder solution of step b) d) mixing the granules from step c) with levocetirizine dihydrochloride, croscarmellose sodium, and E rokris1. Фармацевтическая композиция для перорального введения, содержащая a) монтелукаст или его соль в количестве примерно 10,4 мг b) левоцетиризин или его соль в количестве 5,0 мг, моногидрат лактозы, микрокристаллическую целлюлозу, безводный двухосновный фосфат кальция, кроскармеллозу натрия и ги
